Alafi Capital's $2.8M Private Placement Purchase Lifts CalciMedica Stake to 17.1%
CALC has more than doubled off its 52-week low of $0.461 on light trading volume (0.1× avg).
Summary
Alafi Capital invested $2.8 million in CalciMedica's private placement, buying 3.5 million shares at $0.8033 each and raising its stake to 17.1%. The move is part of a broader $49 million financing and follows other insider buying, underscoring confidence in the company's clinical and financial momentum.
Key Events · Ownership and Investor Activity · CALC
-
Alafi Capital Invests $2.8M
Through the private placement, Alafi Capital bought 3,529,192 shares at $0.8033 per share, for a total investment of approximately $2.8 million.
-
Stake Increases to 17.1%
After the transaction, Alafi Capital holds 5,242,996 shares—17.1% of the outstanding total—including 130,651 warrants at $7.15, cementing its position as a major shareholder.
-
Warrants to Purchase 7.1M Additional Shares
Subject to stockholder approval, Alafi Capital will receive Series A and Series B warrants to purchase 3,529,192 shares each (7,058,384 total), exercisable at $0.8033 and $1.00, respectively.
-
Part of Broader $49M Financing
This investment is part of the private placement announced on June 24, which raised $15 million upfront and could reach up to $49 million if warrants are exercised.
Analysis · CALC · Life Sciences
In CalciMedica's recently closed private placement, venture capital firm Alafi Capital Company LLC—managed by Christopher D. Alafi—acquired 3,529,192 shares at $0.8033 apiece, investing roughly $2.8 million. The purchase pushes Alafi Capital's total holdings to 5,242,996 shares, or 17.1% of the company, including 130,651 warrants with a $7.15 exercise price. This allocation is part of the up to $49 million financing unveiled on June 24, which delivered $15 million upfront. Coming on the heels of other insider purchases in recent weeks, Alafi Capital's participation signals robust institutional conviction in the company's outlook following positive Phase 2b data and a profitable first quarter of 2026. While the $0.8033 purchase price represents a slight discount to the current $0.93 stock price, the overall financing was structured at a premium to market when announced. The filing also reveals that, upon stockholder approval, Alafi Capital will receive Series A and Series B warrants to buy an additional 7,058,384 shares, which could further expand its stake. Such concentrated ownership by a long-term venture investor reduces the float and aligns interests with shareholders, though the potential warrant exercise introduces future dilution.
How filings like this one have moved
In the 30 days to Aug 25, 2026, 37.4% of the 3413 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CALC was trading at $0.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14.7M. The 52-week trading range was $0.46 to $7.20. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.